Phase 2 study of lenvatinib in patients with RET fusion-positive adenocarcinoma of the lung. (February 2017) - Velcheti, V.; Hida, T.; Reckamp, K.L.; Yang, J.C.; Nokihara, H.; Sachdev, P.; Feit, K.; Kubota, T.; Nakada, T.; Dutcus, C.E.; Ren, M.; Tamura, T.